观察联合应用雷替曲塞奥沙利铂吡柔比星经动脉化疗栓塞治疗不可切除原发性肝癌的疗效及安全性观察-医学影像与核医学(介入)专业论文.docxVIP

万方数据 万方数据 Observe the effect and safety of raltitrexed combinatedoxaliplat/pirarubicin in transcatheter hepatic arterial chemoembolization of unresectable primary liver cancer Abstract Objective To observe the effect and safety of raltitrexed combinated oxaliplat/pirarubicin in transcatheter hepatic arterial chemoembolization of unresectable primary liver cancer. Metheods Transcatheter hepatic arterial chemoembolization combinated with lobaplatin /floxuridine/pirarubicin were used to treat 35 unresectable primary liver cancer patients. The DSA/MRI/CT/blood routine examination were used to were evaluated the short term activity and toxicity after 4-5 weeks, the process was repeated if necessary. the results were observed. Results Among the 35 cases, 1 case (2.8%) showed a complete response, 23 cases (65.7%) showed a partial response,8 cases (22.8%) showed stable diseaseand, and 5 cases showed progressive disease（14.2%）,with a total effective rate of 68.5%. The content of AFP dropped by over 50% in 20(57.1%) cases. The rate of recovery was hepatalgia(89.2%) ,ascites (48.3 ％ ), appetite(55.3%), engenargy(30.6%).The median follow-up time（MFT）was 283 days （ 63-557 days ） ,the median pro-gression-free survival was 118.5 days(95%,CI:88.6-147.1days). Conclusion Transcatheter hepatic arterial chemoembolization with Ratitrexed/oxaliplat/pirarubicin is an effective and safe treatment for primary liver cancer. Postgraduate student: Li Jian (Radiology) Directed by Prof. Wang song Keywords: Unresectable primary liver cancer; Raltitrexed; Chemoembolization; Interventional therapy 目 录 引言 ·······································································································1 第一章 资料与方法··················································································2 1.1 研究目的···························································································2 1.2 研究对象····················································································